Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States.

Anand, Sid; Al-Mondhiry, Jafar; Fischer, Katrina; Glaspy, John

Anand, Sid; Al-Mondhiry, Jafar; Fischer, Katrina; Glaspy, John.

Affiliation

Anand S; Division of Hematology & Oncology, University of California , Santa Monica, CA, USA.
Al-Mondhiry J; Division of Hematology & Oncology, University of California , Los Angeles, CA, USA.
Fischer K; Division of Hematology & Oncology, University of California , Los Angeles, CA, USA.
Glaspy J; Division of Hematology & Oncology, University of California , Los Angeles, CA, USA.

Expert Rev Clin Pharmacol ; 14(1): 1-8, 2021 Jan.

Article in En | MEDLINE | ID: mdl-33307871

Subject(s)

Biosimilar Pharmaceuticals/administration & dosage; Epoetin Alfa/administration & dosage; Hematinics/administration & dosage; Anemia/drug therapy; Biosimilar Pharmaceuticals/adverse effects; Drug Approval; Epoetin Alfa/adverse effects; Hematinics/adverse effects; Humans; Quality of Life; United States

Key words

Anemia; biosimilar; development; epo-alfa; epogen; erythropoietin; hematology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biosimilar Pharmaceuticals / Epoetin Alfa / Hematinics Aspects: Patient_preference Limits: Humans Country/Region as subject: America do norte Language: En Journal: Expert Rev Clin Pharmacol Year: 2021 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google